Opinion|Videos|November 30, 2023

Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.


Related to this article

Image of of hot flashes
Hot flashes are common during and after breast and prostate cancer treatment. Here is how hormone treatments compare with the nonhormonal medicines, therapies and comfort steps that national guidelines list, and why the right choice depends on your cancer.
mammogram
Long-term Kisqali data, a new targeted drug, blood tests and AI are among the topics to watch at the 2026 San Antonio Breast Cancer Symposium.